Trial Condition(s):
Magnetic Resonance Imaging, Liver neoplasms
MRI study of Gadovist (1.0 M ) and Magnevist with a single i.v. injection in patients with known or suspected liver lesions
Bayer Identifier:
90932
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
572
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
Gadavist/Gadovist (Gadobutrol, BAY86-4875)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Multicenter, randomized, double blind, inter-individually controlled MRI study of Gadovist (1.0 M ) and Magnevist with a single i.v. injection (0.1 mmol/kg BW) in patients with known or suspected liver lesions and with independent blinded read and assessment of the truth standard
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
